Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
 
Colchicine COVID-19 studies. Recent:
Hunt
Cecconi
Pimenta Bonifácio
Jalal.
Colchicine has been officially adopted for early treatment in 1 country. Submit updates/corrections.
Jun 29
Early, Late, PrEP, PEP Covid Analysis (Preprint) (meta analysis)
meta-analysis
Colchicine for COVID-19: real-time meta analysis of 33 studies
Details   • Statistically significant improvements are seen for mortality, ICU admission, hospitalization, and recovery. 20 studies from 20 independent teams in 13 different countries show statistically significant improvements in isolation (11 for..
Jun 29
Early Hunt et al., Journal of General Internal Medicine, doi:10.1007/s11606-022-07701-3
death, ↓68.0%, p=0.003
Medications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 Veterans
Details   Retrospective 26,508 consecutive COVID+ veterans in the USA, showing lower mortality with multiple treatments including colchicine. Treatment was defined as drugs administered ≥50% of the time within 2 weeks post-COVID+, and may be a cont..
Jun 2
Late Cecconi et al., Scientific Reports, doi:10.1038/s41598-022-13424-6
death, ↓29.4%, p=0.62
Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial
Details   RCT 240 hospitalized patients with COVID-19 pneumonia, mean 9 days from the onset of symptoms, showing no significant differences with colchicine treatment. EudraCT 2020-001841-38.
May 5
Late Jalal et al., Indian Journal of Rheumatology, doi:10.4103/injr.injr_264_21
hosp. time, ↓24.1%, p=0.009
Effectiveness of colchicine among patients with COVID-19 infection: A randomized, open-labeled, clinical trial
Details   Open label RCT of colchicine showing improved recovery with treatment. Only the abstract is currently available. Colchicine 0.5mg bid for 14 days.
Apr 28
Late Pimenta Bonifácio et al., SSRN Electronic Journal, doi:10.2139/ssrn.4095747
death, ↓78.9%, p=0.49
Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care on the treatment of patients hospitalized with moderate to critical Covid-19: a pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)
Details   Open label RCT late stage hospitalized patients in Brazil with 14 colchicine and 16 SOC patients, showing lower mortality and improved recovery with treatment, without statistical significance. Authors note that the colchicine group had o..
Apr 12
Late Gorial et al., Annals of Medicine and Surgery, doi:10.1016/j.amsu.2022.103593
death, ↓66.7%, p=0.62
Randomized controlled trial of colchicine add on to the standard therapy in moderate and severe corona virus Disease-19 infection
Details   RCT with 80 colchicine and 80 control patients, showing improved recovery with treatment. SOC included vitamin C, vitamin D, and zinc.
Apr 5
Meta Yasmin et al., PLOS ONE, doi:10.1371/journal.pone.0266245 (meta analysis)
meta-analysis
Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials
Details   Meta analysis of 5 colchicine RCTs (currently there are RCTs) finding that treatment significantly reduced COVID-19 severity.
Mar 21
PrEPPEP Oztas et al., Journal of Medical Virology, doi:10.1002/jmv.27731
hosp., ↑406.3%, p=0.12
Frequency and Severity of COVID-19 in Patients with Various Rheumatic Diseases Treated Regularly with Colchicine or Hydroxychloroquine
Details   Retrospective 635 HCQ users and 643 household contacts, showing higher risk with colchicine in unadjusted results. Patients with conditions leading to the use of colchicine may have significantly different baseline risk, e.g. .
Feb 2
Late Pourdowlat et al., Phytotherapy Research, doi:10.1002/ptr.7319
hosp., ↓72.8%, p=0.004
Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial
Details   RCT 202 patients in Iran, 102 treated with colchicine, showing lower hospitalization and improved clinical outcomes with treatment.
Jan 31
Late Karakaş et al., The Journal of Infection in Developing Countries, doi:10.3855/jidc.14924
death, ↓12.7%, p=0.72
Reducing length of hospital stay with colchicine
Details   Retrospective 356 hospitalized COVID-19 patients, shorter hospitalization time with colchicine treatment. There were no statistically significant differences for mortality or ICU admission. Significantly lower mortality was seen with high..
Jan 28
PrEPPEP Topless et al., The Lancet Rheumatology, doi:10.1016/S2665-9913(21)00401-X
death, ↓23.2%, p=0.12
Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study
Details   UK Biobank retrospective showing a higher risk of COVID-19 cases and mortality for patients with gout. Among patients with gout, mortality risk was lower for those on colchicine, OR 1.06 [0.60-1.89], compared to those without colchicine, ..
Jan 12
Meta Zein et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2022.102395 (meta analysis)
meta-analysis
Effect of colchicine on mortality in patients with COVID-19 – A systematic review and meta-analysis
Details   Systematic review and meta analysis showing that colchicine was associated with lower mortality in COVID-19 patients: All studies: RR 0.66 [95%CI 0.53, 0.83], p < 0.001; I2: 42% RCTs: RR 0.81 [95%CI 0.54, 1.20], p = 0.29; I2: 10% The RCT ..
Jan 8
PrEPPEP Monserrat Villatoro et al., Pharmaceuticals, doi:10.3390/ph15010078
death, ↓80.0%, p=0.02
A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis
Details   PSM retrospective 3,712 hospitalized patients in Spain, showing lower mortality with existing use of azithromycin, bemiparine, budesonide-formoterol fumarate, cefuroxime, colchicine, enoxaparin, ipratropium bromide, loratadine, mepyramine..
Dec 31
2021
Late Alsultan et al., Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2021/2129006
death, ↓35.7%, p=0.70
Efficacy of Colchicine and Budesonide in Improvement Outcomes of Patients with Coronavirus Infection 2019 in Damascus, Syria: A Randomized Control Trial
Details   Small RCT 49 severe condition hospitalized patients in Syria, showing lower mortality with colchicine and shorter hospitalization time with both colchicine and budesonide (all of these were not statistically significant).
Dec 29
2021
Late Diaz et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.41328
death, ↓12.0%, p=0.30
Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19
Details   Very late stage RCT (O2 88%, 84% on oxygen) with 1,279 hospitalized patients in Argentina, showing lower mortality and lower combined mortality/ventilation, statistically significant only for the combined outcome and per-protocol analysis..
Sep 23
2021
Late Dorward et al., British Journal of General Practice, doi:10.3399/BJGP.2022.0083 (preprint 9/23/2021)
death, ↓69.7%, p=0.43
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
Details   Late treatment RCT with 156 colchicine patients in the UK, showing no significant differences. ISRCTN86534580.
Sep 11
2021
Late Pascual-Figal et al., International Journal of General Medicine, doi:10.2147/IJGM.S329810
death, ↓80.2%, p=0.24
Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID)
Details   RCT with 52 colchicine patients and 51 control patients, showing lower risk of clinical deterioration with treatment. COL-COVID. NCT04350320.
Nov 9
2021
Late Absalón-Aguilar et al., Journal of General Internal Medicine, doi:10.1007/s11606-021-07203-8
death, ↓28.6%, p=0.74
Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID)
Details   Very late stage RCT with 56 colchicine and 60 control patients in Mexico, showing no significant differences.
Jul 10
2021
Late Gaitán-Duarte et al., eClinicalMedicine, doi:10.1016/j.eclinm.2021.101242
death, ↓22.0%, p=0.38
Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial
Details   RCT 633 hospitalized patients in Colombia, 153 treated with colchicine + rosuvastatin, not showing statistically significant differences in outcomes. Improved results were seen with the combination of emtricitabine/tenofovir disoproxil + ..
Jun 30
2021
Late Kevorkian et al., Journal of Infection, doi:10.1016/j.jinf.2021.02.008
progression, ↓95.7%, p=0.0005
Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study
Details   Observational study in France with 28 hospitalized patients treated with prednisone/furosemide/colchicine/salicylate/direct anti-Xa inhibitor, and 40 control patients, showing lower combined mortality, ventilation, or high-flow oxygen the..
Jun 10
2021
Late Hueda-Zavaleta et al., Revista Peruana de Medicina Experimental y Salud Pública, doi:10.17843/rpmesp.2021.382.7158
death, ↓54.0%, p=0.03
Factores asociados a la muerte por COVID-19 en pacientes admitidos en un hospital público en Tacna, Perú
Details   Retrospective 450 late stage (median oxygen saturation 86%) COVID+ hospitalized patients in Peru, showing lower mortality with colchicine treatment.
May 18
2021
Late Recovery Collaborative Group, The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00435-5 (preprint 5/18/2021)
death, ↑1.0%, p=0.77
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Details   RCT with 5,610 colchicine and 5,730 control patients showing mortality RR 1.01 [0.93-1.10]. Very late stage treatment, median 9 days after symptom onset. Baseline oxygen requirements unknown (data is provided but combined with "none&..
Apr 20
2021
Late Mostafaie et al., ClinicalTrials.gov, NCT04392141 (Preprint)
death, ↓83.3%, p=0.11
Colchicine Plus Phenolic Monoterpenes to Treat COVID-19
Details   RCT with 60 patients treated with colchicine and phenolic monoterpenes and 60 control patients in Iran, showing lower mortality with treatment. NCT04392141.
Mar 24
2021
Late Manenti et al., PLOS ONE, doi:10.1371/journal.pone.0248276
death, ↓76.0%, p=0.005
Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study
Details   IPTW retrospective 141 COVID-19 patients (83% hospitalized), 71 treated with colchicine and 70 matched control patients, showing lower mortality and faster recovery with treatment.
Mar 14
2021
Meta Hariyanto et al., Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13488 (meta analysis)
meta-analysis
Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
Details   Meta analysis concluding that colchicine can reduce severity and mortality in COVID‐19 patients, mortality OR 0.43 [0.32-0.58].
Mar 6
2021
Late García-Posada et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.02.013
death, ↓56.9%, p=0.01
Clinical outcomes of patients hospitalized for COVID-19 and evidence-based on the pharmacological management reduce mortality in a region of the Colombian Caribbean
Details   Retrospective 209 hospitalized patients in Colombia, showing lower mortality with antibiotics + LMWH + corticosteroids + colchicine in multivariable analysis.
Feb 28
2021
Late Mareev et al., Kardiologiia, doi:10.18087/cardio.2021.2.n1560
death, ↓79.6%, p=0.49
Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study
Details   Small trial with 21 colchicine patients and 22 control patients in Russia, showing improved recovery with treatment. The trial was originally an RCT, however randomization to the control arm was stopped after 5 patients, and 17 retrospect..
Jan 27
2021
Late Tardif et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00222-8 (preprint 1/27)
death, ↓43.9%, p=0.30
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
Details   RCT for relatively low risk outpatients, 2235 treated with colchicine a mean of 5.3 days after the onset of symptoms, and 2253 controls, showing lower mortality, ventilation, and hospitalization with treatment. NCT04322682.
Jan 7
2021
Late Valerio Pascua et al., PLOS ONE, doi:10.1371/journal.pone.0245025
death, ↓22.8%, p=0.60
A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients
Details   Retrospective 65 ICU patients in the USA and Honduras, showing shorter ICU stay with combined treatment including colchicine, LMWH, tocilizumab, dexamethasone, and methylprednisolone.
Dec 31
2020
Late Mahale et al., Indian Journal of Critical Care Medicine, doi:10.5005/jp-journals-10071-23599
death, ↑7.2%, p=0.83
A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital
Details   Retrospective 134 hospitalized COVID-19 patients in India, showing no significant difference with colchicine treatment in unadjusted results.
Nov 5
2020
Late Rodriguez-Nava et al., Mayo Clinic Proceedings: Innovations, Quality & Outcomes
death, ↓5.5%, p=0.87
Clinical characteristics and risk factors for mortality of hospitalized patients with COVID-19 in a community hospital: A retrospective cohort study
Details   Retrospective 313 patients, mostly critical stage and mostly requiring respiratory support. Confounding by indication likely.
Oct 27
2020
Late Sandhu et al., Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2020/8865954
death, ↓41.7%, p=0.0006
A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection
Details   Prospective cohort study of hospitalized patients in the USA, 34 treated with colchicine, showing lower mortality and intubation with treatment.
Oct 23
2020
Late Pinzón et al., Research Square, doi:10.21203/rs.3.rs-94922/v1 (Preprint)
death, ↓34.5%, p=0.18
Clinical Outcome of Patients with COVID-19 Pneumonia Treated with Corticosteroids and Colchicine in Colombia
Details   Retrospective 301 pneumonia patients in Colombia showing lower mortality with colchicine treatment.
Sep 21
2020
Late Salehzadeh et al., Research Square, doi:10.21203/rs.3.rs-69374/v1 (Preprint)
hosp. time, ↓22.7%, p=0.001
The Impact of Colchicine on The COVID-19 Patients; A Clinical Trial Study
Details   Open label RCT with 100 hospitalized patients in Iran, 50 treated with colchicine, showing shorter hospitalization time. There were no deaths. IRCT20200418047126N1.
Sep 14
2020
Late Scarsi et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217712
death, ↓84.9%, p<0.0001
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
Details   Retrospective 122 colchicine patients and 140 control patients in Italy, showing lower mortality with treatment.
Sep 14
2020
Late Brunetti et al., J. Clin. Med., 9:9, 2961, doi:10.3390/jcm9092961
death, ↓72.7%, p=0.03
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
Details   PSM matched analysis from consecutive hospitalized patients, with 33 colchicine and 33 control matched patients, showing lower mortality with treatment.
Aug 12
2020
Late Lopes et al., RMD Open, doi:10.1136/rmdopen-2020-001455 (preprint 8/12)
death, ↓80.0%, p=0.49
Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
Details   RCT with 36 colchicine and 36 control patients, showing reduced length of hospitalization and oxygen therapy with treatment.
Jun 24
2020
Late Deftereos et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2020.13136
death, ↓77.3%, p=0.19
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial
Details   RCT with 55 patients treated with colchicine and 50 control patients, showing lower mortality and ventilation with treatment. NCT04326790.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit